Pacira BioSciences (PCRX) Tax Provisions (2013 - 2026)

Pacira BioSciences' Tax Provisions history runs 14 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• On a quarterly basis, Tax Provisions fell 46.53% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 77.5% decrease from a year earlier, with the FY2025 full-year figure at $9.8 million, down 73.01% from the prior year.
• Tax Provisions climbed to $2.1 million in Q1 2026 per PCRX's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Tax Provisions topped out at $17.7 million in Q2 2024 and bottomed at -$8.0 million in Q4 2022.
• The 5-year median for Tax Provisions is $3.9 million (2025), against an average of $3.9 million.
• Biggest YoY gain for Tax Provisions was 467.39% in 2023; the steepest drop was 1588.84% in 2023.
• Year by year, Tax Provisions stood at -$8.0 million in 2022, then jumped by 211.1% to $8.8 million in 2023, then climbed by 7.18% to $9.5 million in 2024, then plunged by 111.24% to -$1.1 million in 2025, then jumped by 295.31% to $2.1 million in 2026.
• Per Business Quant, the three latest PCRX Tax Provisions figures stand at $2.1 million (Q1 2026), -$1.1 million (Q4 2025), and $4.1 million (Q3 2025).